

## Role of Prostaglandin D<sub>2</sub> for delayed wound healing in Streptozotocin-induced diabetic mice

Kamauchi Tomoko<sup>1</sup>, Toshio Kubota<sup>1</sup>, Tsukasa Sakurada<sup>2</sup>, Kosuke Aritake<sup>3</sup>

<sup>1</sup>*Ctr. Pharm. Care. Comm. Health, Daiichi Univ. of Pharm.*, <sup>2</sup>*Ctr. Supp. Pharm. Edu., Daiichi Univ. of Pharm.*,  
<sup>3</sup>*Lab. Chem Pharm., Daiichi Univ. of Pharm.*

Delayed wound healing is a major problem in patients with diabetes, which significantly impairs their quality of life. Prostaglandin (PG) D<sub>2</sub> is a major inflammatory lipid mediator synthesized by hematopoietic PGD<sub>2</sub> synthase (H-PGDS) from PGH<sub>2</sub>, a common precursor of all of PGs. In the present study, we investigated the role of PGD<sub>2</sub> in cutaneous wound healing in streptozotocin (STZ)-induced diabetic mice. C57BL/6 mice were injected with 50 mg/kg of STZ intraperitoneally daily for 5 days. Four weeks after the injection of STZ, a full thickness wound was created with an 8-mm diameter biopsy punch on the dorsal of mice. Wound healing was significantly decelerated and cutaneous H-PGDS mRNA was significantly increased in diabetic mice compared with non-diabetic mice. Daily administration of H-PGDS inhibitor for 14 days was significantly promoted wound healing in diabetic mice. These results suggest that PGD<sub>2</sub> involved in delayed wound healing in STZ-induced diabetic mice.